The company will study its vaccine in children, including infants as young as six months and those under 12 in the United States and Canada.
View original article
Contributor: Denise Grady
The company will study its vaccine in children, including infants as young as six months and those under 12 in the United States and Canada.
View original article
Contributor: Denise Grady